Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form

Executive Summary

“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.


Related Content

Shire Course Corrects Lifitegrast And Eyes Ophthalmology Prospects
Financings Of The Fortnight: Recent IPO Slowdown Not Necessarily A Harbinger For A Bad 2014
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Botox And Beyond: Allergan Lays Out Growth Strategy
Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A
The New Ophthalmic Drug Players
Venture Eyes Ophthalmology--And Likes What It Sees
Biotechs Eye Macular Degeneration


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts